Ximelagatran——可望作为首选抗凝剂的新药  

Ximegalaltran-A New Drug may be Used as First Choice of Anticoagulants

作　　者：郭英祥[1] 

机构地区：[1]三明市第二医院心血管内科,福建三明366000

出　　处：《医学综述》2006年第2期104-105,共2页Medical Recapitulate

摘　　要：传统的抗凝剂如华法林,肝素,和低分子量肝素,在预防和治疗动脉性或静脉性血栓栓塞性疾病时有若干缺点。近来在开发的新制剂中,ximegalatran是一种可供口服的直接凝血酶抑制剂,使用简易方便,勿需凝血监测。近几年来,已进行了许多多中心、随机、对照、Ⅲ期临床试验,结果表明,ximegalaltran在疗效和安全性上至少等同于或优于上述抗凝剂,约6%患者有一过性丙氨酸转氨酶升高。许多作者提出,ximegalaltran可望作为首选的抗凝剂。The traditional anticoagulants, such as wadarin, heparin, and low molecular weight heparin, in the prevention and treatment of arterial and venous thromboembolic disorders, have some disadvantages. Ximagalatran which is a new agent developed reantely is an oral direct thrombin inhibitor. It is easy and convenient to use without the need for coagulation monitering. Recently, many mniticantered, randomized, controlled, Phase Ⅲ clinical trials had been performed. Results showed the efficacy and safety of ximegalatran were at least,equal or superior to above anticoagulants. About 6% patients had a transient elevation of alanine aminotransferase. A lot of authors suggested that ximegalatran may be used as a first choice of anticoagulant.

关 键 词：Ximegalatatran 抗凝剂 血栓栓塞症 

分 类 号：R973.2[医药卫生—药品]